Innocenti F - Search Results

1

Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report.

Bocci G, Danesi R, Allegrini G, Innocenti F, Di Paolo A, Falcone A, Conte PF, Del Tacca M. Bocci G, et al. Among authors: innocenti f. Eur J Clin Pharmacol. 2002 Dec;58(9):593-5. doi: 10.1007/s00228-002-0534-6. Eur J Clin Pharmacol. 2002. PMID: 12602342

2

Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice.

Innocenti F, Danesi R, Di Paolo A, Agen C, Nardini D, Bocci G, Del Tacca M. Innocenti F, et al. Drug Metab Dispos. 1995 Jul;23(7):713-7. Drug Metab Dispos. 1995. PMID: 7587959

3

Dissociation between in vitro cytotoxicity and in vivo cardiotoxicity of two new anthracyclines: 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin and 4'-deoxy-4'-iodo-doxorubicin.

Pinna A, Agen C, Di Paolo A, Innocenti F, Nardini D, Danesi R, Del Tacca M. Pinna A, et al. Among authors: innocenti f. J Environ Pathol Toxicol Oncol. 1994;13(1):25-31. J Environ Pathol Toxicol Oncol. 1994. PMID: 7823290

4

Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate.

Innocenti F, Danesi R, Di Paolo A, Loru B, Favre C, Nardi M, Bocci G, Nardini D, Macchia P, Del Tacca M. Innocenti F, et al. Cancer Chemother Pharmacol. 1996;37(5):409-14. doi: 10.1007/s002800050405. Cancer Chemother Pharmacol. 1996. PMID: 8599862

5

Inhibitory effect of the somatostatin analogue SMS 201-995 and cytokines on the proliferation of human colon adenocarcinoma cell lines.

di Paolo A, Bocci G, Innocenti F, Agen C, Nardini D, Danesi R, del Tacca M. di Paolo A, et al. Among authors: innocenti f. Pharmacol Res. 1995 Sep;32(3):135-9. doi: 10.1016/s1043-6618(05)80006-4. Pharmacol Res. 1995. PMID: 8745343

6

Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.

Conte PF, Baldini E, Gennari A, Michelotti A, Salvadori B, Tibaldi C, Danesi R, Innocenti F, Gentile A, Dell'Anna R, Biadi O, Mariani M, Del Tacca M. Conte PF, et al. Among authors: innocenti f. J Clin Oncol. 1997 Jul;15(7):2510-7. doi: 10.1200/JCO.1997.15.7.2510. J Clin Oncol. 1997. PMID: 9215819 Clinical Trial.

7

Chronic administration of suramin induces neurotoxicity in rats.

Di Paolo A, Danesi R, Innocenti F, Bocci G, Nardini D, Fogli S, Pollina L, Rossi B, Del Tacca M. Di Paolo A, et al. Among authors: innocenti f. J Neurol Sci. 1997 Nov 25;152(2):125-31. doi: 10.1016/s0022-510x(97)00185-8. J Neurol Sci. 1997. PMID: 9415531

8

Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo.

Bocci G, Danesi R, Benelli U, Innocenti F, Di Paolo A, Fogli S, Del Tacca M. Bocci G, et al. Among authors: innocenti f. Cancer Chemother Pharmacol. 1999;43(3):205-12. doi: 10.1007/s002800050885. Cancer Chemother Pharmacol. 1999. PMID: 9923550

9

Metabolism of 6-mercaptopurine in the erythrocytes, liver, and kidney of rats during multiple-dose regimens.

Innocenti F, Danesi R, Bocci G, Fogli S, Di Paolo A, Del Tacca M. Innocenti F, et al. Cancer Chemother Pharmacol. 1999;43(2):133-40. doi: 10.1007/s002800050873. Cancer Chemother Pharmacol. 1999. PMID: 9923818

10

An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma.

Fogli S, Danesi R, Innocenti F, Di Paolo A, Bocci G, Barbara C, Del Tacca M. Fogli S, et al. Among authors: innocenti f. Ther Drug Monit. 1999 Jun;21(3):367-75. doi: 10.1097/00007691-199906000-00022. Ther Drug Monit. 1999. PMID: 10365655 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

411 results

Search Page